Lysosomal storage disorder treatment moving into proof-of-concept phase
A company formed to develop protein therapeutics to treat lysosomal storage diseases — rare genetic disorders that affect the metabolism of certain natural biological substances in cells — is raising $5 million in a series A financing round, according to a filing with the U.S. Securities and Exchange Commission With the investment, the company is […]